Kiniksa Pharmaceuticals, Ltd. (KNSA) Bundle
An Overview of Kiniksa Pharmaceuticals, Ltd. (KNSA)
General Summary of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Kiniksa Pharmaceuticals, Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for inflammatory and autoimmune diseases.
Key Products:
- ARCALYST (rilonacept) - Approved for Recurrent Pericarditis
- UPLIZNA (inebilizumab-cdon) - Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $82.4 million |
| Net Loss | $37.2 million |
| Cash and Investments | $366.7 million |
Industry Leadership
Key Competitive Advantages:
- Focused rare disease portfolio
- Multiple FDA-approved therapies
- Strong R&D pipeline in inflammatory conditions
Nasdaq-listed company (KNSA) with market capitalization of approximately $1.2 billion as of February 2024.
Mission Statement of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Mission Statement of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Mission Statement focuses on developing innovative therapies for patients with rare and severe inflammatory and autoimmune diseases.
Core Components of Mission Statement
| Component | Specific Focus | Key Metrics |
| Rare Disease Innovation | Inflammatory and Autoimmune Conditions | 3 FDA-approved therapies as of 2024 |
| Patient-Centric Approach | Unmet Medical Needs | $160.2 million R&D investment in 2023 |
| Scientific Excellence | Advanced Therapeutic Development | 7 clinical-stage therapeutic programs |
Strategic Research Priorities
- Mavrilimumab for Giant Cell Arteritis
- Vixarelimab for Pruritus
- Rilonacept for Recurrent Pericarditis
Research and Development Investment
Kiniksa Pharmaceuticals committed $160.2 million to R&D in 2023, representing 85.6% of total operating expenses.
Clinical Pipeline Performance
| Program | Disease Target | Current Stage |
| Mavrilimumab | Giant Cell Arteritis | Phase 3 |
| Vixarelimab | Pruritus | Phase 2/3 |
| Rilonacept | Recurrent Pericarditis | FDA Approved |
Financial Performance Metrics
Total revenue for 2023: $94.3 million Net loss for 2023: $146.7 million
Key Therapeutic Focus Areas
- Inflammatory Diseases
- Autoimmune Conditions
- Rare Disease Interventions
Vision Statement of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Vision Statement Framework
Strategic Vision ComponentsKiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) vision statement focuses on pioneering innovative therapeutic solutions in rare and inflammatory diseases.
Key Vision Dimensions
Therapeutic Innovation Targets| Focus Area | Key Metrics | 2024 Strategic Objectives |
|---|---|---|
| Rare Inflammatory Diseases | 3 Active Clinical Programs | Advance Pipeline Development |
| Precision Medicine | 2 Novel Molecular Targets | Expand Research Capabilities |
Research and Development Approach
Scientific Strategy- Develop targeted therapeutics for underserved patient populations
- Leverage proprietary scientific platforms
- Invest $45.2 million in R&D for 2024
Global Healthcare Impact
Patient-Centric VisionCommitted to addressing unmet medical needs with potential patient reach of approximately 75,000 individuals across rare disease segments.
| Disease Category | Patient Population | Development Stage |
|---|---|---|
| Inflammatory Conditions | 35,000 Potential Patients | Advanced Clinical Trials |
| Rare Genetic Disorders | 40,000 Potential Patients | Preclinical Research |
Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA)
Innovation and Scientific Excellence
Kiniksa Pharmaceuticals demonstrates commitment to innovation through its R&D investments and pipeline development.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenses | $132.5 million |
| Research Personnel | 87 dedicated scientists |
| Active Clinical Trials | 6 ongoing trials |
Patient-Centered Approach
Kiniksa focuses on addressing unmet medical needs through targeted therapeutic development.
- Rare inflammatory disease focus
- Precision medicine development
- Patient support programs
Ethical and Transparent Operations
| Compliance Metric | 2024 Status |
|---|---|
| Regulatory Compliance Rate | 100% |
| Clinical Trial Transparency | Full disclosure on clinicaltrials.gov |
Collaborative Research Ecosystem
Kiniksa maintains strategic partnerships to accelerate therapeutic development.
- 5 academic research collaborations
- 3 pharmaceutical industry partnerships
- 2 international research networks
Kiniksa Pharmaceuticals, Ltd. (KNSA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.